TOTAL: $820.93M | ||||
| Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details (Date) |
Adamis Pharmaceuticals Corp. (OTC BB:ADMP) |
Private placement of common stock |
40S |
$10 |
Adamis signed a $10M deal with Estes Holdings Ltd., selling 40M shares at 25 cents each (11/12) |
Allon Therapeutics Inc. (Canada; TSX:NPC) |
Private financing |
N/A |
$10 |
Allon closed a $10M financing with Isar Pharma KS (11/3) |
Anacor Pharmaceuticals Inc. (ANAC) |
Private placement |
2S |
$10 |
Anacor raised $10M with a private placement of 2M shares at $5 a share to funds affiliated with existing investor Venrock Associates (11/29) |
Anavex Life Sciences Corp. (OTC BB:AVXL) |
Private placement of units |
0.397U |
$1.09 |
Anavex raised $1.09M through a private placement of 397,482 units for $2.75 each, with each unit representing one common share and one-half of an 18-month warrant with an exercise price of $4.50 (11/23) |
AVEO Pharmaceuticals Inc. (AVEO) |
Private investment |
4.5S |
$61 |
AVEO raised $61M selling 4.5M shares at $13.50 each to a group of investors; J.P. Morgan Securities LLC and Canaccord Genuity Inc. are joint lead placement agents, and RBC Capital Markets Corp. served as co-placement agent (11/1) |
BiondVax Pharmaceuticals Ltd. (Israel; TASE:BNDX) |
Standby equity |
1.45S |
$1.25 |
BiondVax sold 1.45M shares at NIS3.105 each to YA Global Investments LP (11/11) |
BioTime Inc. (AMEX:BTX) |
Exercise of warrants |
N/A |
$6.97 |
BioTime raised a total of $24.17M over the past 18 months from exercises of warrants; it raised $8M in May, $9.2M in August and $6.97M in November (11/5) |
Clavis Pharma ASA (Norway; OSLO:CLAVIS) |
Private placement of common stock |
4.4S |
$25.7 |
Clavis raised $25.7M in the placement of 4.4M shares at NOK35 ($5.84) per share; ABG Sundial Collier ASA and Carnegie ASA led the placement, and existing and new investors participated (11/19) |
DiaGenic ASA (Norway; OSLO:DIAG) |
Private placement |
60S |
NOK30 ($4.9) |
DiaGenic received proceeds of $4.9M through the allocation of 60M new shares at NOK0.50 per share (11/24) |
Endo Pharmaceuticals Holdings Inc. (ENDP) |
Private offering of senior unsecured notes due 2020 |
N/A |
$400 |
Endo disclosed a private offering of $400M in notes due 2020 (11/16) |
EpiCept Corp. (EPCT) |
Private placement of common stock and warrants |
3.3S and W for 1.3S |
$1.9 |
EpiCept raised $1.9M in the placement; Rodman & Renshaw LLC acted as exclusive placement agent (11/9) |
GeneNews Ltd. (Canada; TSX:GEN) |
Private placement |
N/A |
C$2.1 ($2.09) |
GeneNews raised $2.09M through a unit offering and an offering of five-year senior 15% redeemable convertible secured debentures (11/12) |
iBio Inc. (OTC BB:IBPM) |
Private placement |
N/A |
$1.4 |
iBio completed a placement begun in October, bringing the total raised to $7.4M; Financial Capital Markets acted as placement agent (11/19) |
Lorus Therapeutics Inc. (Canada; TSX:LOR) |
Rights offering |
4.2U |
C$4.6 ($4.58) |
Lorus sold 4.2M units for C$1.11 apiece; each unit consists of one share and one warrant to purchase a share (11/11) |
Lpath Inc. (OTC BB:LPTN) |
Private placement of common stock and warrants |
6.9S and W |
$4.9 |
Lpath closed a private placement of 6.9M shares of Class A stock at 70 cents per share and warrants to purchase the number of shares of Class A stock equal to 50% of the number of common shares they purchased; Griffin Securities Inc., Musket Research Associates Inc. and Andrew Garrett Inc. served as placement agents for the financing (11/18) |
Marina Biotech Inc. (MRNA) |
Securities purchase agreement |
1.8S |
$8.7 |
Marina sold 1.8M shares at $1.84 per share to raise $8.7M; LifeTech Capital acted as placement agent (11/8) |
Neoprobe Corp. (OTC BB:NEOP) |
Registered direct offering |
3.2S |
$6 |
Neoprobe added about $6M in an offering of 3.2M shares priced at $1.90 each (11/9) |
NeoStem Inc. (AMEX:NBS) |
Registered direct offering |
10.6U |
$9.8 |
NeoStem raised $9.8M by offering 10.6M units, each containing one share of Series E, 7%, senior, preferred stock, convertible at $2.0004, to mature on May 20, 2013, and a warrant to purchase 0.25 shares of stock with an exercise price of $2.0874 and 0.0155 shares of common stock; the company raised $9.2M in a concurrent public offering, bringing total proceeds to $19M (11/17) |
Oncolytics Biotech Inc. (Canada; ONCY) |
Bought deal financing |
5.4U |
C$25 ($24.5) |
Oncolytics raised $24.5M through the sale of 5.4M units – each consisting of one common share and one-half of one common share purchase warrant – priced at C$4.60 apiece (11/1) |
PDL BioPharma Inc. (PDLI) |
Private placement of convertible senior notes |
N/A |
$88 |
PDL raised $88M by placing convertible senior notes due 2015; it also exchanged $92M in notes due 2012 with $92M in notes due 2015 (11/8) |
PharmaGap Inc. (Canada; CDNX:GAP) |
Private placement of equity units |
4.1U |
$0.572 |
PharmaGap raised $572,000 issuing 4.1M units, each consisting of one common share and one warrant to purchase a common share, priced at 14 cents per unit (11/22) |
Regenicin Inc. (OTC BB:RGIN) |
Private placement |
N/A |
$0.468 |
Regenicin raised $467,550 through a private placement and converted $500,000 of debt into equity (11/12) |
Sernova Corp. (Canada; CDNX:SVA) |
Private placement of units |
6.67U |
$0.999 |
Sernova raised $998,861 in a private placement (11/8) |
Stem Cell Therapeutics Corp. (Canada; CDNX:SSS) |
Execution of warrants |
12.2W |
C$1.82 ($1.81) |
Stem Cell received proceeds of $1.81M for the execution of 12.2M warrants (11/4) |
Synta Pharmaceuticals Corp. (SNTA) |
Private placement |
1.4S |
$5 |
Synta raised $5M through the sale of 1.4M shares at $3.47 each (11/12) |
Theravance Inc. (THRX) |
Investment |
5.75S |
$129.3 |
GlaxoSmithKline plc purchased 5.75M shares of Theravance for $22.50 per share (11/30) |
|
Notes: This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. # Unless otherwise indicated, shares are traded on the Nasdaq exchange; ** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; TASE = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange. | ||||